• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis.

作者信息

Mohyuddin Ghulam Rehman, Sigle Monia, Chandrasekar Viveksandeep Thoguluva, Aziz Muhammad, Abdallah Al-Ola, Shune Leyla, McClune Brian

机构信息

University of Kansas Cancer Center, Kansas City, KS, USA.

School of Medicine, University of Kansas, Kansas City, KS, USA.

出版信息

Leuk Lymphoma. 2020 Oct;61(10):2519-2522. doi: 10.1080/10428194.2020.1772475. Epub 2020 Jun 6.

DOI:10.1080/10428194.2020.1772475
PMID:32508189
Abstract
摘要

相似文献

1
Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis.抗CD38疗法对具有高危细胞遗传学特征的多发性骨髓瘤的影响：系统评价和荟萃分析。
Leuk Lymphoma. 2020 Oct;61(10):2519-2522. doi: 10.1080/10428194.2020.1772475. Epub 2020 Jun 6.
2
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.基于达雷妥尤单抗的化疗后多发性骨髓瘤患者出现CD38阴性复发
Eur J Haematol. 2017 Aug;99(2):186-189. doi: 10.1111/ejh.12902. Epub 2017 Jun 6.
3
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.序贯使用靶向CD38单克隆抗体治疗复发难治性多发性骨髓瘤的临床疗效：一项多机构研究经验
Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2.
4
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.帕比司他可诱导CD38上调，并增强达雷妥尤单抗的抗骨髓瘤疗效。
Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5.
5
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.肿瘤抑制因子 miR-26a 通过靶向 CD38 可作为多发性骨髓瘤的新型潜在治疗药物。
Cancer Res. 2020 May 15;80(10):2031-2044. doi: 10.1158/0008-5472.CAN-19-1077. Epub 2020 Mar 19.
6
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.在三重难治性多发性骨髓瘤患者中再次使用抗CD38单药治疗是一种可行且安全的方法。
Br J Haematol. 2016 Aug;174(3):473-7. doi: 10.1111/bjh.13776. Epub 2015 Oct 12.
7
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.靶向 CD38 抑制调节性 T 细胞的诱导和功能，减轻多发性骨髓瘤中的免疫抑制。
Clin Cancer Res. 2017 Aug 1;23(15):4290-4300. doi: 10.1158/1078-0432.CCR-16-3192. Epub 2017 Mar 1.
8
Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials.多发性骨髓瘤中基于靶向CD38抗原单克隆抗体疗法的血液学和感染并发症：一项随机对照试验的荟萃分析
Leuk Res. 2021 Nov;110:106714. doi: 10.1016/j.leukres.2021.106714. Epub 2021 Sep 25.
9
Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma.获得性CD38基因缺失作为多发性骨髓瘤中肿瘤抗原逃逸的一种机制。
Blood Adv. 2023 Dec 12;7(23):7235-7238. doi: 10.1182/bloodadvances.2023011295.
10
The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma.抗CD38单克隆抗体和抗HI抗体对一名多发性骨髓瘤患者输血前检测的影响。
Ann Hematol. 2023 Jul;102(7):1961-1962. doi: 10.1007/s00277-023-05251-0. Epub 2023 May 5.

引用本文的文献

1
Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.2020年美国血液学会年会上多发性骨髓瘤治疗的重大进展。
Chronic Dis Transl Med. 2021 Aug 31;7(4):220-226. doi: 10.1016/j.cdtm.2021.08.003. eCollection 2021 Dec.
2
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials.添加达雷妥尤单抗到多发性骨髓瘤基础治疗方案中可显著改善临床结局：一项随机对照试验的系统评价和荟萃分析。
Sci Rep. 2021 Nov 9;11(1):21916. doi: 10.1038/s41598-021-01440-x.
3
The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma.
单克隆抗体在双特异性抗体和嵌合抗原受体T细胞疗法时代对多发性骨髓瘤的作用
Cancers (Basel). 2021 Sep 29;13(19):4909. doi: 10.3390/cancers13194909.